Increased circulating FGF21 level predicts the burden of metabolic demands and risk of vascular diseases in adults with type 2 diabetes-Reference-Cited by-同舟云学术

Increased circulating FGF21 level predicts the burden of metabolic demands and risk of vascular diseases in adults with type 2 diabetes

Published:2023-12-07 Issue:1 Volume:23 Page:
ISSN:1472-6823
Container-title:BMC Endocrine Disorders
language:en
Short-container-title:BMC Endocr Disord

Author:

Liu Zhen,Peng Yue,Li Supeng,Lin Yusheng,Huang Yunfeng,Chen Wenting,Bao Chunhua,Zhou Zengxian,Lin Zhuofeng,Chen Liangmiao

Abstract

Abstract Objectives Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by chronic hyperglycemia and metabolic stress, involved in the stepwise development of cardiovascular complications. Fibroblast growth factor 21 (FGF21) is a novel hepatokine involved in regulating glucose and lipid metabolism, and has been linked to the prediction, treatment, and improvement of prognosis in multiple cardiovascular diseases (CVDs). The aim of this study is to explore the relationship between FGF21 levels and vascular diseases (VDs) including carotid atherosclerosis (CAS) and hypertension (HP) in patients with T2DM. Methods Baseline serum FGF21 was determined in a cross-sectional study of 701 patients with T2DM and 258 healthy control. Results The morbidity of CAS was increased in T2DM patients with HP as compared with those without (p < 0.001). The average serum FGF21 level of healthy was [123.9 (67.2-219.3)]. Baseline FGF21 was significantly higher in those who developed CAS or HP than in those who did not [305.9 (177.2-508.4) vs. 197.2 (129.7-308.3) pg/mL, p < 0.001]. In addition, an elevated serum FGF21 was observed in T2DM patients with HP and CAS than that of T2DM patients with CAS or HP [550.5 (312.6-711.3) vs. 305.9 pg/mL, p < 0.001]. Serum FGF21 levels were positively correlated with body mass index and carotid intima media thicknes (p < 0.05), the association remained significant after adjusting for age and T2DM duration. Furthermore, the multinomial logistic regression showed that serum FGF21 was independently associated with CAS and HP in patients with T2DM after adjustment for demographic and traditional VDs risk factors (p < 0.001). Conclusions Baseline FGF21 is elevated in VDs during diabetes, changes of serum FGF21 levels were appropriately matched to metabolic stress. FGF21can be used as an independent predictor for diagnosing VDs and predicting prognosis.

Funder

China National Funds for Distinguished Young Scientist

National Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Endocrinology, Diabetes and Metabolism

Link

https://link.springer.com/content/pdf/10.1186/s12902-023-01523-y.pdf

Reference32 articles.

1. Chen Y, Zhao X, Wu H. Metabolic stress and Cardiovascular Disease in Diabetes Mellitus: the role of protein O-GlcNAc modification. Arterioscler Thromb Vasc Biol. 2019;39(10):1911–24. https://doi.org/10.1161/ATVBAHA.119.312192.

2. Gonzalez LL, Garrie K, Turner MD. Type 2 Diabetes - an autoinflammatory Disease driven by metabolic stress. Biochim Biophys Acta Mol Basis Dis. 2018;1864(11):3805–23. https://doi.org/10.1016/j.bbadis.2018.08.034.

3. Vinciguerra F, Baratta R, Farina MG, Tita P, Padova G, Vigneri R, et al. Very severely obese patients have a high prevalence of type 2 Diabetes Mellitus and Cardiovascular Disease. Acta Diabetol. 2013;50(3):443–9. https://doi.org/10.1007/s00592-013-0460-3.

4. Zhang Y, Liu D, Long XX, Fang QC, Jia WP, Li HT. The role of FGF21 in the pathogenesis of Cardiovascular Disease. Chin Med J (Engl). 2021;134(24):2931–43. https://doi.org/10.1097/CM9.0000000000001890.

5. Samms RJ, Cheng CC, Fourcaudot M, Heikkinen S, Khattab A, Adams J, et al. FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 Diabetes. Am J Physiol Endocrinol Metab. 2022;323(2):E123–32. https://doi.org/10.1152/ajpendo.00050.2022.